Dr. Christopher Lipinski

Dr. Lipinski is a medicinal chemist with more than 34 years of experience at Pfizer, Inc. In 2002 he retired from the highest scientific position in the worldwide Pfizer research organization (Senior Research Fellow) and now serves as a Drug-Like Properties consultant to Pfizer.

Dr. Lipinski is renowned for his “Rule of Five“; an algorithm for predicting drug compounds likely to show oral activity. His 2001 publication in “Advanced Drug Delivery Reviews“, where the “Rule of Five” first appears, is the most frequently cited medicinal chemistry paper in the last decade and is one of the most cited publications in the journal’s history. He was a recipient of the American Chemical Societies 2004 Medicinal Chemistry award.

Dr. Lipinski is a member of the Medicinal Chemistry section of the American Chemical Society, the American Association of Pharmaceutical Sciences, the Society for Biomolecular Screening and the European Federation of Pharmaceutical Sciences.

He serves on scientific advisory boards for the Global Alliance for Tuberculosis Drug Development, ASDI Biosciences, Advanced Chemistry Development Labs and the Matrical Company. Dr. Lipinski is a consultant for Symyx and the Hereditary Disease Foundation. He is a member of the editorial board of the Journal of Pharmaceutical Sciences, Current Drug Discovery Technology, the highlights advisory board of Nature Reviews Drug Discovery, as well as the advisory boards of several other journals.

He serves on the Conference Advisory Board for Cambridge Healthtech Institute. Since 1984, he has been an adjunct faculty member at Connecticut College in New London CT, and has over 180 publications and invited presentations and 17 issued US patents.

Dr. Lipinski received a B.Sc. degree in chemistry from San Francisco State College in 1965 and a Ph.D. in 1968 in physical organic chemistry from the University of California, Berkeley. He joined Pfizer in 1970 following a National Institutes of General Medical Sciences Postdoctoral Fellowship at the California Institute of Technology.

We chose Melior Discovery because they were responsive and cost effective. We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail. Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.
Sridharan Rajamani, Ph.D., Senior Research Scientist
Gilead Sciences
I have been working with Melior on a number of projects over the course of a few years now. They have been a great partner throughout this time. The scientists whom I have worked with have been great problem-solvers and were customer focused.
Jay Lichter
Avalon Ventures
Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences Indiana University, Department of Chemistry
Because Melior could do the orthotopic intracranial implants, we were able to do survival studies with brain tumor-bearing animals that were treated with our therapy, showing a beautiful survival with our agent versus control. Talk about something that gets your investors going! These beautiful survival curves with our agent versus control and visual photos are in all of our investor decks because… it's powerful.
Bruce Ruggeri, Ph.D.
Modifi Bio
Melior works in many therapeutic areas, like CNS, inflammatory disease, GI, cardiovascular, and oncology. I was very pleased that when it came to doing tumor studies, both subcutaneous and intracranial, they did them well. They reported on the studies on time and did the data analysis really well.
Bruce Ruggeri, Ph.D.
Modifi Bio
Their areas of expertise are extensive, and they are very experienced, responsive, and flexible in terms of how the study is run. Their pricing is reasonable, making them the best option for a young, not well-funded company like ours.
Maxine Gowen
Tamuro Bio
Melior’s team was very experienced and knowledgeable. They were always very open to suggestions and questions, spending a lot of time helping us feel comfortable with the study design. I would give them very high marks.
Maxine Gowen
Tamuro Bio
The most important factors in choosing to work with Melior were the fit between the tests they could run and our needs, as well as their tight budget and proximity. Melior was the best fit for our research goals.
Ira Spector
SFA Therapeutics